Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large drop in short interest in July. As of July 15th, there was short interest totaling 9,927 shares, a drop of 85.3% from the June 30th total of 67,330 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average trading volume of 18,424 shares, the days-to-cover ratio is currently 0.5 days.

Biodexa Pharmaceuticals Stock Performance

Shares of BDRX traded down $0.03 during midday trading on Friday, hitting $1.65. The stock had a trading volume of 63,546 shares, compared to its average volume of 412,269. The business has a 50-day simple moving average of $2.84 and a two-hundred day simple moving average of $4.82. Biodexa Pharmaceuticals has a fifty-two week low of $1.64 and a fifty-two week high of $59.40.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned approximately 14.71% of Biodexa Pharmaceuticals as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Wall Street Zen lowered shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 30th. Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biodexa Pharmaceuticals presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.